Celyad has dosed the first patients in its SHRINK and LINK trials, injecting subjects with CYAD-01, an NKG2D receptor.

SHRINK is an open-label Phase I trial designed to investigate the safety and clinical activity of multiple doses of CYAD-01 as a treatment for patients with resectable liver metastases from colorectal cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of the trial, CYAD-01 will be administered concurrently with the neoadjuvant FOLFOX treatment to the enrolled patients.

The trial’s dose escalation phase includes three dose levels of CYAD-01. At each dose, the patients will be given three successive administrations two weeks apart at the specified dose.

So far, the trial has not reported any adverse events.

"We are particularly satisfied with the lack of on-target/off-tumour toxicity observed to date in the context of the combination of CYAD-01 with chemotherapy."

LINK is an open-label Phase I trial that seeks to analyse the safety and clinical activity of multiple doses of CYAD-01.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial will follow a loco-regional approach while treating patients with CYAD-01 administration by providing a number of hepatic transarterial injections to colorectal cancer patients diagnosed with unresectable liver metastases.

Its dose escalation phase will feature three dose levels of CYAD-01 and will be similar to that of the SHRINK trial.

Celyad CEO Dr Christian Homsy said: “CYAD-01, concurrently administered with standard chemotherapy FOLFOX in SHRINK, or administered through hepatic transarterial injections in LINK appears to have been well–tolerated to date.

“We are particularly satisfied with the lack of on-target/off-tumour toxicity observed to date in the context of the combination of CYAD-01 with chemotherapy.”

Celyad expects to begin the EPITHINK trial of CYAD-01 for the treatment of Acute Myeloid Leukemia (AML) soon.

The company also plans to initiate DEPLETHINK AML and DEPLETHINK CRC trials of CYAD-01 for AML over the next few weeks.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact